GlassScriptPhysician profile
Lavy Clevenger
NPI 1235895954
$1,895.58
in general payments reported to CMS, 2019-2025
13 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $160 · 2024: $526 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Travel and Lodging: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.23 |
| Travel and Lodging | $274.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $829.29 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $418.91 | 2023-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.63 | 2022-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $129.25 | 2022-2025 | Farxiga, Wainua |
| Abiomed | $119.24 | 2024-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $49.51 | 2022-2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $45.21 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.23 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $37.60 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.96 | 2025 | |
| Abbott Laboratories | $20.96 | 2024 | Mitraclip |
| Daiichi Sankyo INC. | $20.19 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $13.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lavy Clevenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.